A new therapeutic paradigm: radioiodine combined with lenvatinib for radioiodine-avid metastatic well-differentiated thyroid cancer
Sign Up to like & getrecommendations! Published in 2025 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001980
Abstract: Purpose Metastatic well-differentiated thyroid cancer (WDTC) has significant morbidity and mortality. Multidisciplinary treatment, including high-dose radioiodine therapy (HDRI), has seldom complete response. Concerns are side effects, radioiodine refractoriness, and systemic metastasis. This study investigates the… read more here.
Keywords: hdri; avid metastatic; radioiodine; metastatic well ... See more keywords